Merck KGaA and Pfizer initiate Phase III study with avelumab in patients with stage IIIb/IV non-small cell lung cancer
21 April 2015 | By Victoria White
Merck KGaA and Pfizer have announced the initiation and first patient treated in the Phase III study of avelumab compared with docetaxel, in patients NSCLC...

































